Cargando…
Early optic neuropathy during pegylated alfa 2-B interferon and ribavirin HCV treatment. A case report
INTRODUCTION: Hepatitis C viral infection (HCV) represents an important health problem worldwide. Natural evolution, with its complications, remains a high cause of mortality and morbidity. Interferon (IFN) treatment, along with ribavirin (RBV), was for several years the standard of care. However, m...
Autores principales: | Chis, Bogdan Augustin, Nicula, Cristina, Dumitrascu, Dan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Iuliu Hatieganu University of Medicine and Pharmacy
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709966/ https://www.ncbi.nlm.nih.gov/pubmed/31460516 http://dx.doi.org/10.15386/mpr-1316 |
Ejemplares similares
-
Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
por: Hartl, Janine, et al.
Publicado: (2012) -
Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
por: Rodríguez-Lojo, R., et al.
Publicado: (2010) -
The influence of anti-HBc status on the sustained virological response rate in HCV-infected patients treated with pegylated interferon alfa 2 and ribavirin
por: Szymanek-Pasternak, Anna, et al.
Publicado: (2016) -
Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
por: Kozielewicz, Dorota, et al.
Publicado: (2018) -
Extensive Psoriasis Induced by Pegylated Interferon Alfa-2a and Ribavirin in the Treatment of Chronic Hepatitis C
por: Kim, Gun-Wook, et al.
Publicado: (2013)